An amylin analog is a synthetic peptide built on human amylin, the 37-residue hormone (UniProt P10997) that pancreatic beta cells release alongside insulin. The native sequence aggregates into amyloid fibrils, so every analog in use is a redesign that keeps the receptor-binding character while suppressing that aggregation. Pramlintide, approved in the United States in 2005, does it with three proline substitutions; cagrilintide and eloralintide, both investigational, add a fatty-diacid side chain to extend circulating time.
This primer covers the parent hormone's structure, why amyloid formation is the central design problem, the receptor complexes these peptides act through, and how the three best-characterized analogs differ in sequence, mass and regulatory position.
The parent hormone
Human amylin, also called islet amyloid polypeptide (IAPP), is catalogued in UniProt as P10997. The entry describes an 89-residue precursor: a signal sequence (residues 1–22), a short propeptide, the 37-residue mature peptide (residues 34–70), and a C-terminal propeptide that is removed during processing.
| Property | Value |
|---|---|
| Names | Amylin; islet amyloid polypeptide (IAPP); diabetes-associated peptide |
| UniProt | P10997 (human) |
| Precursor length | 89 residues |
| Mature peptide | 37 residues (precursor positions 34–70) |
| Sequence | KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY |
| Disulfide bond | Cys2–Cys7 (precursor Cys35–Cys40) |
| C-terminus | Tyrosine amide (amidated, not a free acid) |
| Receptors | Calcitonin receptor (CALCR) with RAMP1, RAMP2 or RAMP3 |
Two post-translational features are structurally essential and are reproduced in every analog. The first is the disulfide between Cys2 and Cys7, which closes a small N-terminal ring. The second is the amidated C-terminal tyrosine: the mature peptide ends in -CONH2, not -COOH. A synthetic amylin analog made with a free acid C-terminus is a different molecule, and this is one of the first things worth confirming on a certificate of analysis.
UniProt's functional summary describes amylin as a glucoregulatory hormone that acts through the calcitonin receptor–RAMP complexes and that can also bind the calcitonin receptor without a RAMP, with selectivity for the amylin receptors.
The amyloid problem
Human amylin is one of the best-known amyloid-forming peptides in biology; deposits of it in pancreatic islets gave the molecule its alternative name. Kruse and colleagues open their 2021 description of cagrilintide's development by calling this propensity a hallmark of the hormone and a challenge for molecular design.
The practical consequence is that the native human sequence is difficult to formulate and difficult to work with, because a solution can nucleate fibrils and change composition over time. Rat amylin, which carries prolines in the aggregation-prone middle region, does not fibrillize in the same way, and that observation is the basis of the first successful analog.
Three analogs compared
| Pramlintide | Cagrilintide | Eloralintide (LY3841136) | |
|---|---|---|---|
| Design | A25P, S28P, S29P substitutions in human amylin | Lipidated, sequence-engineered amylin analog | Lipidated, sequence-engineered amylin analog |
| Length | 37 residues | 37 residues | 37 residues |
| Formula | C171H267N51O53S2 (free peptide) | C194H312N54O59S2 | C201H319N49O65S2 |
| Molecular weight | 3949.4 | 4409 | 4526 |
| CAS number | — | 1415456-99-3 | 2883634-40-8 |
| PubChem CID | — | 171397054 | 175663130 |
| Receptor profile | Amylin-receptor selective | Non-selective across amylin and calcitonin receptors | AMY1R-preferring |
| Status | FDA-approved 2005 (SYMLIN, pramlintide acetate) | Investigational | Investigational |
Pramlintide. The FDA label for SYMLIN describes pramlintide as a synthetic analog of human amylin: a 37-amino-acid polypeptide differing from the human sequence by replacement with proline at positions 25 (alanine), 28 (serine) and 29 (serine), supplied as an acetate salt. The drug substance is a white powder, soluble in water, with the free peptide formula C171H267N51O53S2 and a molecular weight of 3949.4. Those three prolines sit in the region most responsible for fibril formation, and they are the entire structural difference between an amyloidogenic hormone and a manufacturable peptide.
Cagrilintide. Kruse and colleagues published the development account in the Journal of Medicinal Chemistry in 2021, describing the structure-activity work that produced a stable, lipidated, long-acting amylin analog, designated AM833 in the pharmacology literature. The PubChem systematic name for the molecule begins with a 20-carbon diacid substituent, the same class of acylation chemistry used to extend circulating time in other long-acting peptides. Fletcher and colleagues profiled it across 25 endpoints in J Pharmacol Exp Ther in 2021 and characterized it as a non-selective agonist of calcitonin-family receptors, active at both the amylin receptors and the calcitonin receptor, with a receptor binding, activation and regulation profile distinct from the selective and non-selective comparators they tested.
Eloralintide. Briere and colleagues reported the discovery work in Molecular Metabolism in 2025. In cell lines expressing individual receptors, eloralintide preferentially activated the human amylin 1 receptor, by about 12-fold over the calcitonin receptor and 11-fold over the amylin 3 receptor; in rat receptors, both AMY1R and AMY3R were activated more potently than CTR. The same paper reported a randomized, placebo-controlled Phase 1 trial (NCT05295940), and a 48-week Phase 2 trial was published in The Lancet in 2025 by Billings and colleagues. The program has since moved into Phase 3, for example a trial in participants with obstructive sleep apnea and obesity or overweight (NCT07369011).
Both cagrilintide and eloralintide are profiled individually elsewhere on this blog: see cagrilintide and eloralintide.
The receptors
Amylin does not have a dedicated receptor gene. Its receptors are built from the calcitonin receptor, a class B G protein-coupled receptor, in complex with one of three receptor activity-modifying proteins:
| Complex | Components | Common name |
|---|---|---|
| AMY1 | CALCR + RAMP1 | Amylin 1 receptor |
| AMY2 | CALCR + RAMP2 | Amylin 2 receptor |
| AMY3 | CALCR + RAMP3 | Amylin 3 receptor |
RAMPs are single-pass membrane proteins that change the pharmacology of the receptor they chaperone: the same calcitonin receptor behaves differently depending on which RAMP is present. This is why amylin pharmacology is reported as a profile across several receptor complexes rather than as a single affinity value, and why terms like "selective" and "non-selective" appear so often in this literature. A compound may prefer AMY1 over AMY3, or activate the bare calcitonin receptor as well, and these differences are measured in cell lines engineered to express one defined complex at a time.
Amylin analogs are frequently studied alongside incretin peptides, which act through an unrelated receptor family; that side of the biology is covered in the GLP-1 receptor agonist primer.
Regulatory status
Pramlintide is approved in the United States. SYMLIN (pramlintide acetate) injection holds NDA 021332, with an initial US approval in 2005, and is labeled as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin.
Cagrilintide is investigational. It has no marketing authorization, and trial registries list ongoing Phase 3 studies of cagrilintide alone and in combination with semaglutide. The combination product, CagriSema, was filed with FDA as a New Drug Application in December 2025; a filing is not an approval, and no decision is recorded in the sources cited here.
Eloralintide is investigational, with Phase 1 and Phase 2 trials published and Phase 3 studies registered.
Anti-doping. None of the three peptides is named in the 2026 World Anti-Doping Agency Prohibited List. For unapproved compounds, the list's S0 class covers pharmacological substances that are not addressed elsewhere on it and that have no current approval by a governmental regulatory authority for human use.
Material sold by Anhydrolabs is supplied for in-vitro laboratory research only, and is not for human or veterinary diagnosis, treatment, or consumption.
Laboratory handling
Cagrilintide and eloralintide are supplied as lyophilized powders in vacuum-sealed vials, on the cagrilintide and eloralintide catalog pages and in 10-vial kits. Amylin analogs bring three handling considerations that shorter peptides do not.
Aggregation. This family is defined by its tendency to self-associate. Even with aggregation-suppressing substitutions, prepare solutions fresh where the experiment allows, avoid vigorous agitation and foaming, and consider filtering stock solutions to remove any preformed aggregates that would act as seeds. Turbidity or a visible haze in a solution that was clear is a reason to stop and re-examine the material rather than to proceed.
Lipidation changes solubility. A peptide carrying a C20 diacid chain is amphiphilic and behaves unlike an unmodified peptide of the same length: it can be slow to wet, it binds readily to plastic and glass surfaces, and it often dissolves more easily in a mildly alkaline buffer than in plain water. Follow the solvent stated on the certificate of analysis, and take the general approach from how to reconstitute lyophilized peptides.
Disulfide and amide. The Cys2–Cys7 bond must stay intact, so keep reducing agents out of buffers intended for the native molecule; a reduced species reads 2 Da heavier by mass spectrometry. The C-terminal amide is worth verifying too, since a free-acid impurity is 1 Da heavier than the amide and is a known by-product of solid-phase synthesis on the wrong resin.
Storage. Keep sealed powders frozen, dry and dark; warm vials to room temperature before opening; and store solutions as single-use frozen aliquots. The detail is in how to store peptides and on the storage and handling page. More posts on this side of the chemistry are collected under peptide science.


